Endocrine News - The Leading Magazine for Endocrinologists

Advocacy
- Research

Endocrine Society Discusses ARPA-H with Congress, NIH, and OSTP

When President Joe Biden’s budget for fiscal year 2022 was introduced this summer, many biomedical research advocates took note of a new line item that would direct $6.5 billion over three years to a new Advanced Research Projects Agency for Health (ARPA-H) to be housed at the National Institutes of Health (NIH). While we were...

Tildacerfont Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia

Patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) may benefit from the drug tildacerfont, according to the results from two Phase 2 clinical studies recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Chris N. Barnes, PhD, of Spruce Biosciences (who funded the trial), point out that...

Advocacy

Endocrine Society Priorities Included in Appropriations Legislation Advancing in House

Last month the House of Representatives advanced the fiscal year 2022 Labor, Health, and Human Services and Education (LHHS) appropriations bill, which provides funding for the National Institutes of Health (NIH) and several other Society priorities. We were extremely pleased to see a base appropriation for the NIH that was consistent with our request of...

FDA Clears iOS App to Simplify Diabetes Management

The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...

Devil in the Details: The Impact of the First Interchangeable Biosimilar Insulin

[Editor’s Note: This post has been updated to include comments from Rita Kalyani, MD.] When the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product last month, many were hailing this as a breakthrough in treating diabetes. The impacts could be immediately felt by people rationing their insulin due to cost as...

2021 Visionary: Q&A with Teresa K. Woodruff

Endocrine News talks with Teresa K. Woodruff, PhD, recipient of the 2021 Endocrine Society Gerald D. Aurbach Award for Outstanding Translational Research about what the award means to her and how she came to focus her life’s work on oncofertility, a phrase that she first coined in 2006. Teresa K. Woodruff, PhD, is no stranger to...

Recognition and Responsibility

Hydelene B. Dominguez, MD, the first winner of the Endocrine Society’s C. Wayne Bardin International Travel Award, talks to Endocrine News about how her Filipino community inspired her to pursue research on radioactive refractory thyroid cancer, as well as her excitement at the prospect of attending ENDO 2022 in Atlanta. Aside from being the first...

FDA Approves First Weekly Injectable Suspension Type 2 Diabetes Treatment in Certain Pediatric Populations

A once-weekly injectable suspension has been approved in the U.S. for the treatment of type 2 diabetes. Marketed by AstraZeneca as BYDUREON BCise (exenatide extended-release), it has been shown to to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and...

Endocrine news on twitter